Name:	ions_AdditionalAmountOfCommonStockRequiredToBePurchasedInTheFuture
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The total amount of consideration to be allocated to the identified stand-alone units of accounting under the collaboration agreement.

No definition available.

Name:	ions_AllocableArrangementConsideration
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The percentage change in the selling price factor applied to a multiple-deliverable arrangement to determine the change to the allocation of the consideration to a specific unit of accounting that would result.

No definition available.

Name:	ions_AssumedChangeInEstimatedSellingPriceOfProduct
Namespace Prefix:	ions_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The amount of change to the allocation of the consideration to a specific unit of accounting that would result from a specified change in the selling price factor applied to a multiple-deliverable arrangement.

No definition available.

Name:	ions_ChangeInAmountOfRevenueFromProductForAssumedChangeInSellingPrice
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of consideration allocated to delivery of the active pharmaceutical ingredient (API) for the drug under the collaboration agreement.

No definition available.

Name:	ions_ConsiderationAllocatedToDeliveryOfActivePharmaceuticalIngredient
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of consideration allocated to development activities for the drug under the collaboration agreement.

No definition available.

Name:	ions_ConsiderationAllocatedToDevelopmentActivities
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount of consideration allocated to the exclusive license of the drug under the collaboration agreement.

No definition available.

Name:	ions_ConsiderationAllocatedToExclusiveLicense
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The number of agreements with the collaboration partner, including collaboration and other types of agreements.

No definition available.

Name:	ions_NumberOfAgreements
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of categories of milestone events used in collaboration agreements to determine milestone payments.

No definition available.

Name:	ions_NumberOfCategoriesOfMilestoneEvents
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of drugs licensed after the partner(s) exercised their option to license the Company's drugs under their respective collaboration agreements.

No definition available.

Name:	ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreements
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of drugs with an exclusive option that could be exercised to develop and commercialize the drug and a license fee is paid under the collaboration agreement. The collaboration partner will assume all further global development, regulatory and commercialization activities for the licensed drug.

No definition available.

Name:	ions_NumberOfDrugsWithExclusiveOptionThatCouldBeExercised
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of partners that exercised their option to license drugs from the Company under a collaboration agreement.

No definition available.

Name:	ions_NumberOfPartnersThatExercisedOptionToLicenseDrugs
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of stages in the life-cycle of drugs.

No definition available.

Name:	ions_NumberOfStagesInLifeCycleOfDrugs
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The amount of payments received during the period for advancing programs under the collaboration agreement.

No definition available.

Name:	ions_PaymentReceivedForAdvancingPrograms
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The percentage change to the allocation of the consideration to a specific unit of accounting that would result from a specified change in the selling price factor applied to a multiple-deliverable arrangement.

No definition available.

Name:	ions_PercentageChangeInAmountOfRevenueFromProductForAssumedChangeInSellingPrice
Namespace Prefix:	ions_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

The average time period to complete Investigational New Drug (IND)-enabling animal studies for a new development candidate, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ions_PeriodToCompleteINDEnablingAnimalStudies
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to complete a Phase 1 clinical trial, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ions_PeriodToCompletePhase1ClinicalTrial
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to complete a Phase 2 clinical trial, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ions_PeriodToCompletePhase2ClinicalTrial
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to complete a Phase 3 clinical trial, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ions_PeriodToCompletePhase3ClinicalTrial
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to obtain marketing authorization from the applicable regulatory agency after an application is submitted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ions_PeriodToObtainMarketingAuthorizationFromApplicableRegulatoryAgency
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The average time period to prepare and submit regulatory filngs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	ions_PeriodToPrepareAndSubmitRegulatoryFilings
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount of a pre-specified sales threshold that can be used to trigger a commercialization milestone payment under the collaboration agreement.

No definition available.

Name:	ions_PreSpecifiedProductSalesThresholdIncludedInCommercializationMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the number of separate units of accounting requiring the allocation of consideration for revenue recognition purposes under the multi-deliverable arrangement.

No definition available.

Name:	ions_RevenueRecognitionMultiDeliverableArrangementNumberOfUnitsOfAccounting
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The amount of upfront payments received during the period under the collaboration agreement.

No definition available.

Name:	ions_UpfrontPaymentReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The cash inflow from the additional capital contribution to the entity.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- References

No definition available.

Name:	us-gaap_RevenueRecognitionAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Number of new stock issued during the period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_CounterpartyNameAxis=ions_NovartisInternationalAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: